Tuesday, October 04, 2016 10:43:22 AM
1223P HLA-A2 and immune checkpoints inhibitors in advanced
non-small cell lung cancer (NSCLC) patients
L. Mezquita1, M. Charrier2, J. Lahmar1, J. Remon1, M.V. Bluthgen1, F. Facchinetti1,
D. Planchard1, A. Gazzah3, L. Dupraz2, J. Adam4, N. Chaput2, B. Besse1
1
Medical Oncology Department, Gustave Roussy, Villejuif, France, 2
Laboratory of
Immunomonitoring in Oncology, UMS 3655 CNRS/US 23 INSERM, Gustave
Roussy, Villejuif, France, 3
Drug Development Department (DITEP), Gustave
Roussy, Villejuif, France, 4
Pathology Department, Gustave Roussy, Villejuif, France
Background: The class I human leucocyte antigen (HLA) molecules play a critical role
in tumor recognition by T cells and the loss of expression seems to be an escape
mechanism of antitumoral immunity. Novel immune-targeting cancer vaccines are
currently developped in HLA-A2 positive patients for modulating the T cells immune
response. We hypothesized that HLA-A2 status could influence the prognosis and
response to immunotherapy.
Methods: Advanced NSCLC patients treated with nivolumab, pembrolizumab or
atezolizumab were prospectively included from Nov. 2013 to Apr. 2016 in our institute.
HLA-A2 status was analysed by flow cytometry; PDL1 was analysed by
immunohistochemistry. Clinical and biological data were collected at baseline and after
cycle 1. Statistical analysis was performed with SPSS v.20.
Results: Out of 125 patients treated, HLA-A2 status was available for 30 patients. 50%
were male, median age was 61 years (29-77); 86% were smokers and 83% had
performance status 0-1. 18 (60%) were adenocarcinoma, 7 (23.3%) squamous and 5
(16.7%) others histologies. 2 NSCLC were EGFRmut, 2 ALK positive, 7 KRASmut, 19
wildtype. PDL1 expression was positive in 8 patients (26.7%), negative in 2 (6.7%) and
unknown in 20 (66.7%). The median of previous lines of treatment was 1 (1-8). The
patient and tumor characteristics were well balanced according to HLA-A2. The
median progression free survival to immunotherapy (iPFS) was 1.47 months
[confidence interval (CI) 95% 1.18-1.7]. HLA-A2 positive status was correlated with
longer iPFS [2.04 vs. 1.3 months, log-rank; p = 0.020]. The median overall survival
(OS) was 38.05 months [CI 95% 8.94-67.16]. The median OS was 55.9 months [CI 95%
9.4-102.15] vs. 22.5 months [CI 95% 0- 54.8] in HLA-A2 positive vs. negative patients
(p = 0.340). In univariate analysis, there was no correlation between outcome and
patient or tumor characteristics.
Conclusions: Our preliminary results suggest that HLA-A2 status could influence the
outcome in NSCLC patients treated with immune checkpoint inhibitors. An updated
analysis on 59 patients will be presented.
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM